EBS News and Press, Emergent Biosolutions Inc. From 07/30/20

Image source: The Motley Fool. Emergent BioSolutions Inc   (NYSE: EBS) Q2 2020 Earnings Call Jul 30, 2020 , 5:00 p.m. ET Operator Continue reading

Emergent Biosolutions (NYSE: EBS ) : Q2 Non-GAAP EPS of $1.98; GAAP EPS of $1.73. More news on: Emergent BioSolutions Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutions Current quarter and year-to-date performance reflect strength of core medical countermeasure business and increased impact of CDMO business ...

The Problem You are not going to find a standard valuation metric to validate the stock price of any of the leading COVID-19 vaccines that are currently in clinical trials. To the contrary, the measure is market potential if, perchance, one or more of these companies gain regulatory approval...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

Chalk up another contract to manufacture a coronavirus vaccine for Emergent BioSolutions (NYSE: EBS) . This time from a repeat customer: AstraZeneca (NYSE: AZN) . Emergent BioSolutions, which is focused on bioterrorism and emergent diseases but also has a contract-manufacturing divis...

Emergent BioSolutions (NYSE: EBS ) has signed an agreement with AstraZeneca (NYSE: AZN )  to provide contract development and manufacturing (CDMO) services for large-scale drug substance manufacturing for AZN's COVID-19 vaccine candidate, AZD1222. More news on: Emergent BioSoluti...

Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supply Agreement is valued at approximately $174 million through 2021 and brings the total AstraZeneca commitment to $261 million Parties may en...

Rather than wowing speculators with promises of a scientific breakthrough, Emergent BioSolutions ' (NYSE: EBS) coronavirus strategy positions the company as the go-to resource for vaccine manufacturing support. Aside from its ever-increasing number of contract manufacturing agreements with ma...

GAITHERSBURG, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400 ® index, effective prior to the open of trading on Friday, Jul...